C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.46 AUD 8.15% Market Closed
Market Cap: 162.3m AUD
Have any thoughts about
Cyclopharm Ltd?
Write Note

Gross Margin
Cyclopharm Ltd

64.8%
Current
69%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
64.8%
=
Gross Profit
18.8m
/
Revenue
29m

Gross Margin Across Competitors

Country AU
Market Cap 162.3m AUD
Gross Margin
65%
Country US
Market Cap 205.2B USD
Gross Margin
56%
Country US
Market Cap 193.1B USD
Gross Margin
67%
Country US
Market Cap 148.6B USD
Gross Margin
64%
Country US
Market Cap 132.9B USD
Gross Margin
69%
Country IE
Market Cap 109.9B USD
Gross Margin
65%
Country US
Market Cap 64.8B USD
Gross Margin
45%
Country DE
Market Cap 56.6B EUR
Gross Margin
38%
Country CN
Market Cap 326.2B CNY
Gross Margin
64%
Country US
Market Cap 42.2B USD
Gross Margin
79%
Country US
Market Cap 37.7B USD
Gross Margin
41%
No Stocks Found

Cyclopharm Ltd
Glance View

Market Cap
162.3m AUD
Industry
Health Care

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC Intrinsic Value
2.05 AUD
Undervaluation 29%
Intrinsic Value
Price
C

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
64.8%
=
Gross Profit
18.8m
/
Revenue
29m
What is the Gross Margin of Cyclopharm Ltd?

Based on Cyclopharm Ltd's most recent financial statements, the company has Gross Margin of 64.8%.